Business Wire

CA-FORESCOUT

14.9.2023 14:01:27 CEST | Business Wire | Press release

Share
U.S. Department of Defense Awards Forescout New Comply-to-Connect Contract as Program Enters Step Four

Forescout, a global cybersecurity leader and a key provider of cybersecurity solutions to the U.S. Department of Defense (DoD), announced today that it secured a new contract with the DoD as it enters year four of the highly successful Comply-to-Connect (C2C) program. The program’s next stage will be to configure delivered capabilities to enforce zero trust access principles across the DoD Information Network (DoDIN) enterprise and bring the DoD closer to the goals set forth in the Department’s Zero Trust Strategy.

As advocated by the Defense Information System Agency (DISA) C2C Program Management Office (PMO), the new contract also delivers additional capabilities to the C2C platform that revolutionize security of Operational Technology networks and integrates risk management and decision making into the existing C2C platform. This addition further positions the DoD to apply NIST zero trust principles to millions of devices across the enterprise. Implementation of zero trust principles using Forescout’s C2C capabilities is already being accomplished in some areas of the Army, via an initiative being taught at Fort Gordon school houses and referenced in Defense Acquisition University.

With the first three steps of the program – visibility, compliance assessment, and automated remediation – well underway, administrators can now use Forescout’s orchestration capabilities to manage policy enforcement points to create the desired effects on an individual user/device/access request basis. Additionally, Forescout’s continuous monitoring capabilities are at work to ensure connected devices don’t fall out of compliance due to files getting corrupted, simple administrative mistakes, or malicious adversarial actions, all of which occur daily on the DoDIN.

C2C is one of the largest government cybersecurity initiatives in the world delivering enterprise scale capabilities for managing cyber operational risk. With the program now in its fourth year, automated control of access to and within the DoDIN will ensure that each network user has the access necessary to achieve their mission without exposing other users to threats that could impact their ability to complete their mission.

“We are proud to once again be trusted by so many organizations to secure the backbone of their operations: the networks that connect everything,” said Barry Mainz, CEO, Forescout. “Each DoDIN user should have confidence that their slice of the network is secure and ready for them to accomplish their mission. That’s what we are delivering through C2C.”

Today, the Forescout platform provides comprehensive capabilities for the DoD’s C2C security framework that enables the critical first pillar of DISA’s zero trust program called Thunderdome. This includes:

  • Network-based discovery and classification of assets, including an expanding set of “unmanaged” assets that are unable to operate agents (C2C Steps 1 and 2)
  • Integration with other enterprise solutions such as Identity, Credential, and Access Management (ICAM); Security Information Event Management (SIEM); and Vulnerability Assessment products to automate compliance of the cybersecurity posture and establish trust for every connecting asset (C2C Step 3)
  • Orchestration of policy enforcement points across the infrastructure to enforce network access control and segmentation of assets as well as complete situational awareness of the network posture (C2C Steps 4 and 5)

“We look forward to introducing cloud-based advanced threat analysis tools into the C2C program’s portfolio of capabilities and adding further value on DoD’s zero trust journey,” added Mainz. “We’ve really just begun to unleash the power of our platform within the DoD. The best is still ahead.”

Additional Resources

About Forescout

Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats. www.forescout.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230914036853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye